High Q Technologies
Overview
High Q Technologies Inc. is a biotechnology company specializing in the development of quantum-enabled scientific instruments for ultra-high sensitivity biophysical and chemical analysis, particularly through electron paramagnetic resonance (EPR) spectroscopy. Founded in 2013 and based in Waterloo, Ontario, Canada, the company was founded by individuals associated with significant advancements in quantum technology. As of 2025, High Q Technologies has secured a total of $10.2 million in funding. The company is backed by Quantum Valley Investments and Blackberry co-founders Mike Lazaridis and Doug Fregin.
Recent Developments
- January 2025: High Q Technologies announced the commercial availability and first sale of its revolutionary FATHOM™ EPR spectrometer to a consortium of researchers led by Prof. Reza Dastvan at the Saint Louis University School of Medicine. This device is notable for its proprietary quantum-based sensor and fully automated operation, aimed at transforming the field of EPR for protein dynamics.
- February 2024: The company secured $3.75 million in funding from the Government of Canada to support the expansion of its protein measurement platform for drug discovery, underlining its strategic role in advancing scientific tools for biophysical research.
- 2023-2024: High Q Technologies has actively participated in several key scientific conferences, promoting its FATHOM EPR spectrometer and engaging with the international scientific community to enhance its product visibility and application prospects.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2013 |
| Headquarters | Waterloo, Ontario, Canada |
| Founders | Not explicitly mentioned in recent sources |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | Quantum Valley Investments, Government of Canada |
| Industry | Biotechnology Research |
| Number of Employees | 11-50 |
Early History
High Q Technologies was founded in 2013 with a mission to harness the power of quantum technology for applications in biotechnology. The company emerged from the intellectual ecosystem fostered by the University of Waterloo's Institute for Quantum Computing. Initially operating as a developer of scientific instruments for biophysical analysis, High Q quickly made a mark by focusing on electron paramagnetic resonance (EPR) spectroscopy, a niche but impactful field in structural biology and drug research. Early collaborations with academic institutions and its strategic location in the Quantum Valley have underscored its commitment to innovation and excellence.
Company Profile and Achievements
High Q Technologies is recognized for integrating modern microwave quantum optics into EPR spectroscopy, setting a new standard in protein structure determination.
- 2019: Raised $6.5 million in seed funding, marking its initial financial milestone.
- 2023: Launched the FATHOM™ EPR Spectrometer, revolutionizing EPR spectroscopy with features such as automated calibration and analysis, and significantly lower sample volume requirements.
- Partnerships: Backed by significant investments and collaborations, including partnerships with the University of Waterloo and government bodies.
- Innovations: The company has consistently built upon its patented technologies, derived from advances in experimental quantum computing, to enhance sensitivity and speed in chemical analysis.
Current Operations and Market Position
High Q Technologies continues to influence the industry with its advanced quantum-enabled spectroscopic solutions. Its flagship product, the FATHOM™ EPR Spectrometer, plays a crucial role in protein dynamics research, a field critical to future drug discovery and development. The company is positioned as a leader in its niche, leveraging its partnerships and technological edge to maintain competitive advantages and expand its market reach.
Conclusion
High Q Technologies stands out as a pioneering force in the application of quantum technologies in scientific research. Its innovative approach to enhancing electron paramagnetic resonance spectroscopy offers significant potential in drug discovery and structural biology. Looking ahead, High Q is poised for continued impact and expansion, driven by its strategic investments and collaborations, making substantial contributions to both the scientific community and the broader biotechnology industry.